JHP Pharmaceuticals to Produce Clinical Batches of Innovative
Cardiac Drug
PARSIPPANY, NJ July 25, 2011
--
JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.
Stuart Hinchen, President and CEO of JHP stated, “We are pleased that JHP was chosen to produce clinical batches for this important customer. Our cGMP compliance record, coupled with an experienced staff, gives us an advantage in meeting customer needs throughout a product’s life cycle, starting with clinical batch production.”
“We know that customers want to seamlessly transition from clinical batch production to product launch and then commercialization. JHP has the right scale and experience to meet customer needs across the product life cycle.”
Hinchen also noted, “During the last seven months, we successfully completed FDA and EMA audits and entered agreements with five new customers. These agreements are examples of how our approach to continuing investment allows us to focus on customer needs, which results in an internal infrastructure that supports ongoing sustainable growth.”
JHP’s Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.
About JHP Pharmaceuticals, LLC
JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables and ophthalmic/otic products, for large and small pharmaceutical and biotech organizations.
JHP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, a clinical filling line, four lyophilizers and an ophthalmic filling line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.
JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit
www.jhppharma.com.
Additional Press Releases
|
07/25/11 |
|
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug |
 |
|
Webpage
|
PDF Format |
|
|
|
|
07/06/11 |
|
JHP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/05/11 |
|
JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®,
Coly-Mycin® M and Pitocin® |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/24/11 |
|
JHP Pharmaceuticals Announces Chief
Executive Officer Succession |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
03/28/11 |
|
JHP Pharmaceuticals Announces Multi-Year
Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
02/24/11 |
|
JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
01/27/11 |
|
JHP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/29/10 |
|
JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
05/10/10 |
|
JHP Pharmaceuticals Announces Successful
Completion of FDA and EMEA GMP Audits |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
09/28/09 |
|
JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
08/20/08 |
|
JHP Pharmaceuticals & SpePharm complete
purchaseof Dantrium® (dantrolene sodium)
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/16/07 |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility
To JHP Pharmaceuticals |
|
|
|
Webpage
|
PDF Format |
|
|
|
